| Zacks Company Profile for Alimera Sciences, Inc. (ALIM : NSDQ) |
|
|
| |
| • Company Description |
| Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
Number of Employees: 154 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $5.01 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 24,980 shares |
| Shares Outstanding: 7.00 (millions) |
| Market Capitalization: $35.08 (millions) |
| Beta: 1.48 |
| 52 Week High: $10.50 |
| 52 Week Low: $3.94 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-12.41% |
-4.10% |
| 12 Week |
6.60% |
19.80% |
| Year To Date |
-2.34% |
19.31% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Richard S. Eiswirth, Jr. - Chief Executive Officer; President and Director
C. Daniel Myers - Chairman of the Board of Directors
J. Philip Jones - Chief Financial Officer
James Largent - Lead Independent Director
Brian K. Halak, Ph.D. - Director
|
|
Peer Information
Alimera Sciences, Inc. (CORR.)
Alimera Sciences, Inc. (RSPI)
Alimera Sciences, Inc. (CGXP)
Alimera Sciences, Inc. (BGEN)
Alimera Sciences, Inc. (GTBP)
Alimera Sciences, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 016259202
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/12/22
|
|
Share - Related Items
Shares Outstanding: 7.00
Most Recent Split Date: 11.00 (0.07:1)
Beta: 1.48
Market Capitalization: $35.08 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.61 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-2.08 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/12/22 |
|
|
|
| |
